+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antithrombin Market by Type, Source, Form, Dosage Form, Therapeutic Application, End User - Global Forecast 2026-2032- Product Image
Antithrombin Market by Type, Source, Form, Dosage Form, Therapeutic Application, End User - Global Forecast 2026-2032- Product Image
Sale

Antithrombin Market by Type, Source, Form, Dosage Form, Therapeutic Application, End User - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904661
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antithrombin Market is projected to reach USD 818.65 Million in 2026. It is expected to continue growing at a CAGR of 4.96%, reaching USD 1.09 Billion by 2032.

Antithrombin is a critical endogenous anticoagulant protein that inhibits thrombin and factor Xa, making it central to thrombosis prevention, heparin responsiveness, and coagulation balance. The antithrombin market spans plasma-derived antithrombin concentrates, recombinant antithrombin, diagnostic activity and antigen testing, and clinical use in hereditary antithrombin deficiency, acquired antithrombin depletion, perioperative care, pregnancy, neonatal care, extracorporeal circulation, and selected critical-care settings.

Demand is shaped by rare-disease diagnosis, expanding thrombophilia testing, hospital protocols for high-risk surgery and obstetrics, and the clinical need to manage thrombotic risk when conventional anticoagulation is insufficient or heparin response is reduced. Market participants must navigate biologics regulation, plasma supply constraints, recombinant manufacturing complexity, pharmacovigilance requirements, cold-chain controls, and evidence-based prescribing standards.

Transformative Shifts in the Antithrombin Landscape

The landscape is shifting from episodic treatment toward precision coagulation management. Clinicians increasingly combine antithrombin activity assays, antigen measurement, genetic evaluation, patient history, family history, and thrombotic-risk stratification to determine when antithrombin replacement is clinically appropriate, especially in hereditary deficiency and high-risk pregnancy, delivery, surgery, or thromboembolic disease.

Biologic manufacturing is also changing. Plasma-derived products remain important because of established clinical use, while recombinant antithrombin provides an alternative supply model that reduces direct dependence on human plasma collection. At the same time, stricter cold-chain management, batch traceability, viral safety standards, donor-screening expectations, hemovigilance, and real-world evidence requirements are redefining competitive advantage across hospital and specialty-care channels.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is influencing antithrombin through diagnostics, clinical decision support, pharmacovigilance, and manufacturing analytics. AI-enabled laboratory systems can help identify abnormal coagulation patterns, flag potential heparin resistance, support review of antithrombin activity trends, and prioritize confirmatory testing when integrated with validated clinical workflows and clinician oversight.

In biomanufacturing, machine learning supports process monitoring, batch-quality prediction, deviation detection, yield optimization, inventory planning, and cold-chain risk management. The cumulative impact is not replacement of physician judgment, but better signal detection, more consistent production, stronger safety surveillance, and improved targeting of antithrombin therapy in patients with verified clinical need.

Key Regional Insights

North America remains a highly regulated and clinically advanced antithrombin market, supported by specialized thrombosis centers, biologics oversight by the U.S. FDA and Health Canada, hospital-based coagulation laboratories, and strong use of evidence-based anticoagulation protocols. Europe benefits from EMA-aligned pharmacovigilance, established rare-disease pathways, national reimbursement systems, and broad adoption of coagulation diagnostics across Germany, France, Italy, Spain, the United Kingdom, and the Nordic region.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in advanced hospital infrastructure, thrombophilia testing, biologics governance, intensive-care capability, and access to specialty medicines. Latin America shows selective growth through Brazil and Mexico, where tertiary hospitals, private specialty networks, and reference laboratories drive adoption. The Middle East, led by GCC healthcare modernization, is improving access to specialty biologics, critical-care services, and centralized procurement, while Africa remains constrained by limited advanced diagnostics, fragmented procurement, uneven cold-chain capacity, and lower availability of rare-disease therapies outside major urban centers.

Key Group Insights

Within ASEAN, antithrombin adoption is tied to tertiary-care expansion, medical tourism hubs, and improving laboratory capacity in markets such as Singapore, Thailand, Malaysia, Indonesia, the Philippines, and Vietnam. The GCC is strengthening access through centralized procurement, specialty hospitals, national health transformation programs, and investments in intensive care, maternal health, and advanced biologics availability.

The European Union provides a mature regulatory and pharmacovigilance environment for plasma-derived and recombinant products, supported by rare-disease frameworks, hemovigilance systems, and harmonized quality standards. BRICS countries combine large patient pools and growing hospital capacity with uneven access to thrombophilia testing, biologic therapies, and reimbursement. G7 markets lead in clinical guidelines, reimbursement sophistication, diagnostic infrastructure, and rare-disease care models. NATO countries, many of which overlap with Europe and North America, benefit from resilient medical supply-chain planning, advanced hospital systems, and established emergency preparedness for critical biologics.

Key Country Insights

The United States is the most influential commercial environment due to FDA-regulated biologics, specialist thrombosis care, advanced coagulation laboratories, and strong hospital purchasing systems, while Canada emphasizes safety assessment, reimbursement review, provincial formulary access, and coordinated specialty care. Mexico and Brazil show demand through tertiary hospitals, private-sector specialty care, and expanding reference laboratory services. The United Kingdom, Germany, France, Italy, and Spain remain important European markets because of advanced coagulation laboratories, structured biologics oversight, national health-system purchasing, and established clinical pathways for thrombosis and rare hematologic conditions.

Russia maintains demand through major urban hospitals but faces procurement, reimbursement, and access variability. China and India are high-potential markets as diagnostic capacity, intensive-care infrastructure, and biologics access expand, though affordability, regional disparities, and reimbursement coverage remain important. Japan, South Korea, and Australia demonstrate high clinical standards, strong laboratory infrastructure, careful biologics governance, and mature hospital protocols for anticoagulation management, perioperative care, and high-risk obstetrics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that clearly defines when antithrombin replacement improves clinical outcomes, especially in hereditary antithrombin deficiency, high-risk obstetrics, perioperative thrombosis prevention, extracorporeal circulation, heparin resistance, and selected critical-care scenarios. Building partnerships with thrombosis centers, maternal-fetal medicine programs, intensive-care units, cardiac surgery teams, neonatology services, and coagulation laboratories can improve appropriate diagnosis and treatment selection.

Manufacturers should strengthen plasma-supply resilience, recombinant production capability, cold-chain visibility, validated quality systems, lot traceability, and pharmacovigilance reporting. Commercial teams should invest in clinician education, reimbursement dossiers, real-world evidence, diagnostic awareness, and region-specific access strategies that reflect local laboratory capacity, biologics procurement systems, rare-disease pathways, and hospital formulary requirements.

Research Methodology

This executive summary is based on verified secondary research, including regulatory product information, clinical guideline themes, peer-reviewed coagulation literature, rare-disease references, biologics safety standards, hospital procurement patterns, and public health-system indicators. The analysis emphasizes validated clinical applications, established diagnostic workflows, and documented healthcare infrastructure factors rather than speculative off-label demand.

Research inputs were synthesized through market segmentation by product type, source, clinical indication, end user, region, economic group, and country. Findings were cross-checked against known biologics regulatory pathways, antithrombin deficiency epidemiology, diagnostic workflow standards, coagulation laboratory practices, pharmacovigilance expectations, plasma-derived product safety requirements, and healthcare infrastructure maturity.

Conclusion

The antithrombin market is a specialized biologics and diagnostics space shaped by rare hereditary deficiency, acquired coagulation disorders, heparin responsiveness, critical-care needs, and the broader evolution of precision thrombosis management. Growth in clinical relevance depends on accurate testing, appropriate patient selection, reliable supply, strong pharmacovigilance, and robust evidence supporting therapeutic value.

Organizations that combine high-quality manufacturing, regulatory discipline, AI-enabled operational intelligence, validated safety monitoring, and targeted clinical education will be best positioned to compete. The strongest opportunities will emerge where advanced coagulation diagnostics, specialty care access, hospital protocol adoption, and biologics reimbursement mature together.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antithrombin Market, by Type
7.1. Alpha
7.2. Beta
8. Antithrombin Market, by Source
8.1. Human Plasma
8.2. Recombinant
9. Antithrombin Market, by Form
9.1. Liquid
9.2. Powder
10. Antithrombin Market, by Dosage Form
10.1. Injectable
10.2. Oral Suspensions
11. Antithrombin Market, by Therapeutic Application
11.1. Acquired Deficiency
11.2. Acute Pancreatitis
11.3. Congenital Deficiency
11.4. Disseminated Intravascular Coagulation
11.5. Liver Disease
11.6. Sepsis Associated Coagulopathy
12. Antithrombin Market, by End User
12.1. Ambulatory Surgical Centers
12.2. Clinics
12.3. Diagnostic Laboratories
12.4. Hospitals
12.5. Research Institutes
13. Asia-Pacific Antithrombin Market
14. North America Antithrombin Market
15. Latin America Antithrombin Market
16. Europe Antithrombin Market
17. Middle East Antithrombin Market
18. Africa Antithrombin Market
19. ASEAN Antithrombin Market
20. GCC Antithrombin Market
21. European Union Antithrombin Market
22. BRICS Antithrombin Market
23. G7 Antithrombin Market
24. NATO Antithrombin Market
25. United States Antithrombin Market
26. Canada Antithrombin Market
27. Mexico Antithrombin Market
28. Brazil Antithrombin Market
29. United Kingdom Antithrombin Market
30. Germany Antithrombin Market
31. France Antithrombin Market
32. Russia Antithrombin Market
33. Italy Antithrombin Market
34. Spain Antithrombin Market
35. China Antithrombin Market
36. India Antithrombin Market
37. Japan Antithrombin Market
38. Australia Antithrombin Market
39. South Korea Antithrombin Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Baxter International Inc.
41.2. Bio Products Laboratory Ltd.
41.3. Bio-Techne Corporation
41.4. Biocon Ltd.
41.5. Boehringer Ingelheim Pharma GmbH & Co. KG
41.6. China Biologic Products, Inc.
41.7. Diapharma Group, Inc.
41.8. European Medicines Agency
41.9. F. Hoffmann-La Roche Ltd
41.10. Fresenius Kabi
41.11. Grifols, S.A.
41.12. Jiangsu Hengrui Medicine Co., Ltd.
41.13. Kedrion Biopharma S.p.A.
41.14. Kyowa Kirin Co., Ltd.
41.15. Lee Biosolutions, Inc.
41.16. LFB USA, Inc.
41.17. Merck KGaA
41.18. Nihon Pharmaceutical Co., Ltd
41.19. Novartis AG
41.20. Octapharma AG
41.21. Pfizer Inc.
41.22. rEVO Biologics Inc.
41.23. Scripps Laboratories
41.24. Siemens Healthineers AG
41.25. Takeda Pharmaceutical Company Limited
41.26. Thermo Fisher Scientific Inc
List of Figures
FIGURE 1. GLOBAL ANTITHROMBIN MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTITHROMBIN MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTITHROMBIN MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTITHROMBIN MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CANADA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. MEXICO ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. BRAZIL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. GERMANY ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. RUSSIA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. SPAIN ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CHINA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. INDIA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. JAPAN ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTITHROMBIN MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ALPHA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ALPHA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ALPHA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BETA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BETA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BETA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL HUMAN PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL HUMAN PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HUMAN PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ACQUIRED DEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ACQUIRED DEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ACQUIRED DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ACUTE PANCREATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ACUTE PANCREATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ACUTE PANCREATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CONGENITAL DEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CONGENITAL DEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CONGENITAL DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DISSEMINATED INTRAVASCULAR COAGULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DISSEMINATED INTRAVASCULAR COAGULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DISSEMINATED INTRAVASCULAR COAGULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL LIVER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LIVER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LIVER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SEPSIS ASSOCIATED COAGULOPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SEPSIS ASSOCIATED COAGULOPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SEPSIS ASSOCIATED COAGULOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. EUROPE ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 94. EUROPE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 95. EUROPE ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 96. EUROPE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 97. EUROPE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. AFRICA ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 108. AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 109. AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 110. AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 111. AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 112. AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. ASEAN ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. ASEAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 115. ASEAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 116. ASEAN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 117. ASEAN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 118. ASEAN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 119. ASEAN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. GCC ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GCC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 122. GCC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 123. GCC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 124. GCC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 125. GCC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 126. GCC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. BRICS ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. BRICS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 136. BRICS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 137. BRICS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 138. BRICS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 139. BRICS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 140. BRICS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. G7 ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. G7 ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 143. G7 ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 144. G7 ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 145. G7 ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 146. G7 ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 147. G7 ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. NATO ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 149. NATO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 150. NATO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 151. NATO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 152. NATO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 153. NATO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 154. NATO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. CANADA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 163. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 164. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 165. CANADA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 166. CANADA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 167. CANADA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 168. CANADA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. MEXICO ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 170. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 171. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 172. MEXICO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 173. MEXICO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 174. MEXICO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 175. MEXICO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. BRAZIL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 177. BRAZIL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 178. BRAZIL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 179. BRAZIL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 180. BRAZIL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 181. BRAZIL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 182. BRAZIL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 186. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 187. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 188. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. GERMANY ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 191. GERMANY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 192. GERMANY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 193. GERMANY ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 194. GERMANY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 195. GERMANY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 196. GERMANY ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. FRANCE ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 198. FRANCE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 199. FRANCE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 200. FRANCE ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 201. FRANCE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 202. FRANCE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 203. FRANCE ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. RUSSIA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 205. RUSSIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 206. RUSSIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 207. RUSSIA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 208. RUSSIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 209. RUSSIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 210. RUSSIA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. ITALY ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. ITALY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 213. ITALY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 214. ITALY ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 215. ITALY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 216. ITALY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 217. ITALY ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. SPAIN ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 219. SPAIN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 220. SPAIN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 221. SPAIN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 222. SPAIN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 223. SPAIN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 224. SPAIN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. CHINA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 226. CHINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 227. CHINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 228. CHINA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 229. CHINA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 230. CHINA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 231. CHINA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. INDIA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 233. INDIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 234. INDIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 235. INDIA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 236. INDIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 237. INDIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 238. INDIA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. JAPAN ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 240. JAPAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 241. JAPAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 242. JAPAN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 243. JAPAN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 244. JAPAN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 245. JAPAN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. AUSTRALIA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 247. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 248. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 249. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 250. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 251. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 252. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. SOUTH KOREA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 255. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 256. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 257. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 258. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 259. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Antithrombin market report include:
  • Baxter International Inc.
  • Bio Products Laboratory Ltd.
  • Bio-Techne Corporation
  • Biocon Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • China Biologic Products, Inc.
  • Diapharma Group, Inc.
  • European Medicines Agency
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi
  • Grifols, S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Kedrion Biopharma S.p.A.
  • Kyowa Kirin Co., Ltd.
  • Lee Biosolutions, Inc.
  • LFB USA, Inc.
  • Merck KGaA
  • Nihon Pharmaceutical Co., Ltd
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • rEVO Biologics Inc.
  • Scripps Laboratories
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc

Table Information

Report AttributeDetails
No. of Pages185
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 818.65 Million
Forecasted Market Value ( USD ) by 2032 $ 1090 Million
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Antithrombin - Global Strategic Business Report - Product Image

Antithrombin - Global Strategic Business Report

  • Report
  • 227 Pages
  • Global
From
Management of Antithrombin Market - Global Forecast 2025-2030 - Product Image

Management of Antithrombin Market - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Antithrombin Market Forecast to 2033 - Product Image

Antithrombin Market Forecast to 2033

  • Report
  • 100 Pages
  • Global
From
Antithrombin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Antithrombin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 186 Pages
  • Global
From
Antithrombin Market Outlook 2026-2034: Market Share and Growth Analysis by Usage (Therapeutics, Diagnostics, Research, Other), Source, Type, Route of Administration - Product Image

Antithrombin Market Outlook 2026-2034: Market Share and Growth Analysis by Usage (Therapeutics, Diagnostics, Research, Other), Source, Type, Route of Administration

  • Report
  • 160 Pages
  • Global
From

About the Antithrombin Test Market

The Antithrombin Test is a coagulation and hemostasis test used to measure the activity of antithrombin, a protein in the blood that helps to prevent the formation of blood clots. It is used to diagnose and monitor conditions such as thrombophilia, a disorder that increases the risk of blood clots, and to assess the risk of thromboembolism, a condition in which a clot forms in a blood vessel and travels to another part of the body. The test is performed using a sample of blood, which is then analyzed in a laboratory. The Antithrombin Test market is composed of a variety of companies that provide testing services, reagents, and instruments. These companies include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Ortho Clinical Diagnostics, Sysmex Corporation, and Grifols. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.